Are you need IT Support Engineer? Free Consultant
Report ID: HC0056
Pages: 165
Base Year: 2025
Format: PDF
Historical Date: 2020-2024
MARKET SCOPE:
The global basal insulin market is projected to grow significantly, registering a CAGR of 9.6% during the forecast period (2025 – 2034).
The basal insulin market is primarily driven by the increasing prevalence of diabetes worldwide – specifically type 2 diabetes – as a result of obesity, a sedentary lifestyle, and poor dietary choices. As reported in its 2019 report, the International Diabetes Federation reports that the number of adults diagnosed with diabetes is expected to soar into the future and lead to a continuous demand of long lasting insulins. Additionally, the increased growth of the geriatric population, which has a higher prevalence of chronic metabolic conditions than the rest of the population, is driving the market. These demographic and lifestyle changes are solidifying the significant role of basal insulin in glucose control, and over time will solidify the significance of the therapy in the health of millions of patients.
Furthermore, the increase in digital technology developments and modern delivery methods has contributed significantly to the market’s growth. New delivery innovations such as prefilled insulin pens, smart pumps, and patch delivery devices can enhance diabetes self-management by increasing convenience, accuracy, and the likelihood of patients using the treatments correctly. The combinations of delivery and continuous glucose monitoring (CGM) systems, mobile health apps, and artificial intelligence-enabled digital diagnostics enable individualized diabetes management in real-time. The increasing use of biosimilar basal insulins is also broadening access to treatment through reduced costs in treatment, particularly in low-resource countries. In addition, favorable policies from governments and reimbursement coverage programs and public health initiatives aimed at disease improvement all support improved diabetes management and are inducing larger and further adoption of basal insulin. Taken together, these factors are providing sustainable growth for the basal insulin market, in both developed and emerging economies.
MARKET OVERVIEW:
Driver: Rising Prevalence of Diabetes Driving Demand for Basal Insulin
The rising incidence of diabetes, particularly type 2 diabetes, is a key contributor to the basal insulin market. Widening rates of obesity, inactivity, and less healthy eating habits produce increasing levels of insulin resistance, creating an important role for basal insulin in maintaining long-term glucose control. With diabetes increasingly becoming one of the foremost global health issues, the use of long-acting insulin that are effective (but also safe to use) is steadily on the rise.
Further, older adults (who are at even greater risk of chronic metabolic disorders), are putting more insulin-dependent diabetes into the healthcare system. This means that broadly-based efforts to emphasize early intervention and ongoing management from healthcare systems will be needed; and that typically emphasizes the importance of basal insulin function in long-term diabetes management.
Restraint: High Cost of Insulin Limiting Accessibility
Despite being essential for millions of patients, the high price of insulin remains a considerable barrier to market growth. The complex manufacturing process, lack of competition hinges in a particular area of the market, and overwhelming strength of brand products ensure high prices. This limits affordability, and in low- and middle-income economies, many patients are resorting to reducing dosage and delaying treatment. Even in developed regions, healthcare systems continue to experience significant economic strain when reimbursing the cost of a patient’s insulin therapy. Although biosimilars are helping to drive costs down, achieving widespread affordability is challenging and is holding back basal insulin from having serious impact in addressing the diabetes burden worldwide.
Opportunity: Expansion of Biosimilar Basal Insulins Unlocking Market Growth
The availability and subsequent acceptance of biosimilar basal insulins creates a tremendous opportunity within the market. These products carry similar safety and efficacy as branded products, but more affordable pricing allows for enhanced access to insulin therapy for more of the patient population. This is especially important in many price-sensitive environments, where accessibility has the greatest differential effect on treatment adoption.
Furthermore, supportive government initiatives and regulatory frameworks support biosimilar developing and uptake; consequently, creating further competition and incentivization for affordability and innovation. As more pharmaceutical companies engage in biosimilars manufacturing, it is anticipated that patient access will improve considerably, ultimately enabling biosimilars to be a larger growth driver within the basal insulin market.
SEGMENTATION ANALYSIS:
The Glargine Segment is anticipated to grow significantly during the forecast period
The basal insulin market is categorized into degludec, glargine, and detemir, each offering distinct therapeutic benefits for patients requiring long-acting insulin solutions.
The glargine segment in the basal insulin market is anticipated to continue its dominance during the forecast period, primarily due to its unique efficacy, widespread availability, and established trust in clinical practice. In particular, glargine remains the most commonly prescribed and preferred product due to its prolonged action for stable glucose control. With the introduction of glargine biosimilars in the market enhancing affordability and accessibility, growth should continue in the glargine segment. As the glargine product has a strong brand recognition, in addition to a lengthy usage history during general practice, glargine continues to be the standard in the basal insulin market.
REGIONAL ANALYSIS:
The North America region is set to witness significant growth during the forecast period
The basal insulin market in North America is expected to continue to lead the market during the forecast period. This is mainly attributed to the prevalence of diabetes, solid healthcare infrastructure, and early adoption of innovative insulin therapies. The U.S. and Canada make up a large share of the overall market, with leading pharmaceutical companies with a high commitment to R&D, as well as favorable reimbursement policies which provide more options for access to insulin. Patient awareness and availability of biosimilar products continue to strengthen the U.S. and Canada, making North America the most mature and revenue-generating basal insulin market.
On the other hand, the Asia Pacific basal insulin market is expected to become the fastest growing region, with the growing diabetic population, urbanization, and changing lifestyle creating an increased need for quality insulin therapy. Growth will be primarily driven by China and India with expanding healthcare infrastructure, increasing insurance penetration, and government-led activities to create better patient management for diabetes. The introduction of low-cost biosimilar insulins, improving patient-access to treatment affordability, also facilitates patient access. As chronic disease management matures, including more pharmaceutical and medication presence, expect Asia Pacific to contribute to increasingly important future-growth prospects in the overall basal insulin market.
COMPETITIVE ANALYSIS:
The global basal insulin market is reasonably competitive with mergers, acquisitions, and Type launches. See some of the major key players in the market.
Recent Development:
SCOPE OF THE REPORT:
KEY REASONS TO PURCHASE THIS REPORT:
** In – depth qualitative analysis will be provided in the final report subject to market
Primary and Secondary Research
In order to understand the market in detail we conduct primary and secondary research. We collect as much information as we can from the market experts through primary research. We contact the experts from both demand and supply side and conduct interviews to understand the actual market scenario. In secondary research, we study and gather the data from various secondary sources such as company annual reports, press releases, whitepapers, paid databases, journals, and many other online sources. With the help of the primary interviews, we validate the data collected from secondary sources and get a deep understanding on the subject matter. Post this our team uses statistical tools to analyses the data to arrive at a conclusion and draft it in presentable manner.
Market Size Estimations
Understanding and presenting the data collected is a crucial task. Market sizing is a critical part of the data analysis and this task is performed by using Top-down and bottom-up approaches. In this process, we place different data points, market information and industry trends at a suitable space. This placement helps us presume the estimated & forecast values for coming few years. We use several mathematical and statistical models to estimate the market sizes of different countries and segments. Each of this is further added up to outline the total market. These approaches are individually done on regional/country and segment level.
Data Triangulation
As we arrive at the total market sizes, the market is again broken down into segments and subsegments. This process is called as data triangulation and is implementable wherever applicable. This step not only helps us conclude the overall market engineering process, but also gives an assurance on accuracy of the data generated. The data is triangulated based on studying the market trends, various growth factors, and aspects of both demand and supply side.